Investigating Wnt signaling: A chemogenomic safari

Drug Discovery Today

Volumn 10, Issue 21, 2005, Pages 1467-1474

  McMillan, Michael ^a   Kahn, Michael ^a,b  

^a Institute for Chemical Genomics   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; ICG 001; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

CANCER CELL; CANCER GROWTH; CHEMICAL STRUCTURE; GENE EXPRESSION; GENE LIBRARY; GENE TARGETING; GENETIC ANALYSIS; GENOMICS; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; BETA CATENIN; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG DESIGN; GENE EXPRESSION REGULATION; GENOMICS; PROTEIN TRANSPORT; PYRIMIDINONES; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 26944439459     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03613-5     Document Type: Review

References (62)

1. Liu J. A small-molecule agonist of the Wnt signaling pathway Angew. Chem. Int. Ed. Engl. 44 2005 1987 1990
2. Peterson R.T. Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation Nat Biotechnol. 22 2004 595 599
3. Xin H. High throughput siRNA-based functional target identification J. Biomol. Screen 9 2004 286 293
4. Colca J.R., Harrigan G.G. Photoaffinity labeling strategies in identifying the protein ligands of bioactive small molecules: examples of targeted synthesis of drug analog photoprobes Comb. Chem. High Throughput Screen 7 2004 699 704
5. Tochtrop G.P., King R.W. Target identification strategies in chemical genetics Comb. Chem. High Throughput Screen 7 2004 677 688
6. Burdine L., Kodadek T. Target identification in chemical genetics: the (often) missing link Chem. Biol. 11 2004 593 597
7. Kung C., Shokat K.M. Small-molecule kinase-inhibitor target assessment ChemBioChem 6 2005 523 526
8. Shim J.S., Kwon H.J. Chemical genetics for therapeutic target mining Expert Opin. Ther. Targets 8 2004 653 661
9. Wagner B.K. Chemical genomics: probing protein function using small molecules Am. J. Pharmacogenomics 4 2004 313 320
10. Thorpe D.S. Forward and reverse chemical genetics using SPOS based combinatorial chemistry Comb. Chem. High Throughput Screen 6 2004 623 647
11. Halazy S. Chemical genetics: toward the next generation of molecular medicines Pharmacogenomics 5 2004 757 761
12. Khersonsky S.M., Chang Y.T. Strategies for facilitated forward chemical genomics ChemBioChem 5 2004 903 908
13. Sharom J.R. From large networks to small molecules Curr. Opin. Chem. Biol. 8 2004 81 90
14. Chen E., Ekker S.C. Zebrafish as a genomics research model Curr. Pharm. Biotechnol. 5 2004 409 413
15. Clemons P.A. Complex phenotypic assays in high-throughput screening Curr. Opin. Chem. Biol. 8 2004 334 338
16. Freidinger R. Design and synthesis of novel bioactive peptides and peptidomimetics J. Med. Chem. 46 2003 5553 5565
17. Bain J. The specificities of protein kinase inhibitors: an update Biochem. J. 371 2003 199 204
18. Lepourcelet M. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex Cancer Cell 5 2004 91 102
19. Kaiser E.T., Kedzy F.J. Amphiphilic secondary structure: design of peptide hormones Science 223 1984 249 255
20. Kahn M. Peptide secondary structure mimetics: recent advances and future challenges Synlett 11 1993 821 826
21. Ogbu C.O. Highly efficient and versatile synthesis of libraries of constrained beta-strand mimetics Bioorg. Med. Chem. Lett. 8 1998 2321 2326
22. Eguchi M. Solid phase synthesis and structural analysis of bicyclic b-turn mimetics incorporating functionality at the i to i+3 positions J. Am. Chem. Soc. 121 1999 12204 12205
23. Kim H.O., Kahn M. Recent developments in peptide secondary structure mimetics Res Adv In Organic Chem. 1 2000 43 59
24. Arkin M.R., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing toward the dream Nat. Rev. Drug Discov. 3 2004 301
25. Pagliaro L. Emerging classes of protein-protein inhibitors and new tools for development Curr. Opin. Chem. Biol. 8 2004 442 449
26. Oving I.M., Clevers H.C. Molecular causes of colon cancer Eur. J. Clin. Invest. 32 2002 448 457
27. Moon R.T. The promise and perils of Wnt signaling through beta-catenin Science 296 2002 1644 1646
28. Brantjes H. TCF: Lady Justice casting the final verdict on the outcome of Wnt signaling Biol. Chem. 383 2002 255 261
29. Nelson W.J., Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways Science 303 2004 1483 1487
30. Moon R.T. WNT and beta-catenin signaling: diseases and therapies Nat. Rev. Genet. 5 2004 691 701
31. Fearnhead N.S. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis Br. Med. Bull. 64 2002 27 43
32. Shtutman M. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway Proc. Natl. Acad. Sci. U. S. A. 96 1999 5522 5527
33. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells Nature 398 1999 422 426
34. He T.C. Identification of c-MYC as a target of the APC pathway Science 281 1998 1509 1512
35. Emami K.H. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription Proc. Natl. Acad. Sci. U. S. A. 101 2004 12682 12687
36. Hecht A. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates EMBO J. 19 2000 1839 1850
37. Takemaru K.I., Moon R.T. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression J. Cell Biol. 149 2000 249 254
38. Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation and development Genes Dev. 14 2000 1553 1577
39. Velculescu V.E. Analysis of human transcriptomes Nat. Genet. 23 1999 387 388
40. Ambrosini G. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nat. Med. 3 1997 917 921
41. Li F. Survivin study: what is the next wave? J. Cell. Physiol. 197 2003 8 29
42. Altieri D.C. Validating survivin as a cancer therapeutic target Nat. Rev. Cancer 3 2003 46 54
43. Zhang T. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer Cancer Res. 61 2001 8664 8667
44. Kim P.J. Survivin and molecular pathogenesis of colorectal cancer Lancet 362 2003 205 209
45. Ma H. Differential roles for the coactivators CBP and p300 on TCF/b-catenin mediated survivin gene expression Oncogene 24 2005 3619 3631
46. Girdwood D. P300 transcriptional repression is mediated by SUMO modification Mol. Cell 11 2003 1043 1054
47. Xu Z.X. Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression J. Biol. Chem. 279 2004 1838 1844
48. Zechner D. beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system Dev. Biol. 258 2003 406 418
49. Otero J.J. Beta-catenin signaling is required for neural differentiation of embryonic stem cells Development 131 2004 3545 3557
50. Hirabayashi Y. The Wnt/beta-catenin pathway directs neuronal differentiation of cortical neural precursor cells Development 131 2004 2791 2801
51. Mesulam M.M. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles Neuron 24 1999 521 529
52. Fraser P.E. Presenilin function: connections to Alzheimer's disease and signal transduction Biochem. Soc. Symp. 67 2001 89 100
53. De Strooper B. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein Nature 391 1998 387 390
54. Berezovska O. Notch is expressed in adult brain, is coexpressed with presenilin-1, and is altered in Alzheimer disease J. Neuropathol. Exp. Neurol. 57 1998 738 745
55. Levesque G. Presenilins interact with armadillo proteins including neural-specific plakophilin-related protein and beta-catenin J. Neurochem. 72 1999 999 1008
56. Kang D.E. Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway J. Neurosci. 19 1999 4229 4237
57. Canzoniere D. Dual control of neurogenesis by PC3 through cell cycle inhibition and induction of Math1 J. Neurosci. 24 2004 3355 3369
58. Kowalczyk A. The critical role of cyclin D2 in adult neurogenesis J. Cell Biol. 167 2004 209 213
59. Teo J. Specific inhibition of CBP/b-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation Proc. Natl. Acad. Sci. U. S. A. 102 2005 12171 12176
60. Pardal R. Applying thr principles of stem-cell biology to cancer Nat. Rev. Cancer 3 2003 895 902
61. Weinstein J.N. Neural computing in cancer drug development: predicting mechanism of action Science 258 1992 447
62. van Osdol W.W. Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents J. Natl. Cancer Inst. 86 1994 1853 1859